The start of cell line development represents a significant milestone for biologics innovators: It’s a commitment to a specific molecule and the start of the journey towards IND. By using the latest technologies such as automated multiple microscale bioreactors and high-throughput analytics, it is possible to interrogate clones more closely to determine productivity, manufacturability, and performance at scale and at an early stage. In addition, the data generated can be used to inform process and analytical development. By viewing CLD and manufacturing as different ends of one integrated continuum, it is possible to derisk manufacturing at scale as well as reduce overall time to IND.
Watch the recorded webcast below.